Abstract
Objective
The objective of this study was to utilize computed tomographic peritoneography (CTP)
to assess distribution prior to intraperitoneal chemotherapy for advanced müllerian
cancer.
Methods
Nineteen patients were submitted to CTP. A novel 6-point peritoneal distribution index
was developed and applied to the patients prospectively.
Results
The median peritoneal distribution index was 6 (range, 4–6). The most common region
for incomplete peritoneal distribution correlated to the right subphrenic space.
Conclusion
Further studies are needed to determine the impact of inadequate distribution on recurrence
and survival.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Use of nitrogen mustard in treatment of serous effusions of neoplastic origin.J Am Med Assoc. 1955; 159: 1704-1707
- Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.Cancer Treat Rep. 1978; 62: 1-11
- Intraperitoneal drug delivery of antineoplastics.Drugs. 2001; 61: 1057-1065
- Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.N Engl J Med. 1996; 335: 1950-1955
- Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.J Clin Oncol. 2001; 19: 1001-1007
- Intraperitoneal cisplatin and paclitaxel in ovarian cancer.N Engl J Med. 2006; 354: 34-43
- Clinical announcement: intraperitoneal chemotherapy for ovarian cancer. January 4, 2006.
- Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.Cancer. 2007; 109: 692-702
- Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics.AJR Am J Roentgenol. 1979; 133: 221-223
- Computerized tomography with and without intraperitoneal contrast for determination of intraabdominal fluid distribution and diagnosis of complications in peritoneal dialysis patients.ASAIO Trans. 1990; 36: 95-103
- Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography.Ann Oncol. 1992; 3: 149-154
- Computed tomographic assessment of intraperitoneal fluid distribution prior to intraperitoneal chemotherapy for ovarian cancer.Br J Radiol. 1992; 65: 295-297
- The use of scintigraphic and contrast peritoneography in gynecologic malignancies.Diagn Gynecol Obstet. 1982; 4: 75-78
- SPECT of the peritoneal cavity: method for delineating intraperitoneal fluid distribution.AJR Am J Roentgenol. 1989; 152: 1205-1210
- Anatomic changes in the abdominal cavity during intraperitoneal chemotherapy: prospective study using scintigraphic peritoneography.Bull Cancer. 1993; 80: 345-350
- Prediction of effectiveness of intraperitoneal chemotherapy by intraperitoneal scintigraphy in patients with advanced ovarian carcinoma.Clin Nucl Med. 1994; 19: 600-603
- Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy.Int J Gynecol Cancer. 2003; 13: 196-203
- Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.J Clin Oncol. 2003; 21: 2849-2855
- Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin—a gynecologic oncology group study.J Clin Oncol. 2003; 21: 4350-4355
- Computerized tomography of the abdomen and pelvis with peritoneal administration of soluble contrast (IPC-CT) in detection of residual disease for patients with ovarian cancer.Gynecol Oncol. 1994; 52: 154-160
- Noninvasive monitoring of ovarian cancer: improved results using CT with intraperitoneal contrast combined with immunocytology.Gynecol Oncol. 1994; 53: 103-108
- Complications associated with intraperitoneal chemotherapy catheters.Gynecol Oncol. 2001; 81: 77-81
- Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis.J Am Soc Nephrol. 1994; 4: 1820-1826
Article info
Publication history
Published online: August 12, 2009
Accepted:
May 1,
2009
Received:
March 20,
2009
Identification
Copyright
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
